ALLK Allakos Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALLK

Price (delayed)

$1.065

Market cap

$93.59M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.14

Enterprise value

$65.36M

Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company's lead antibody, lirentelimab ...

Highlights
Allakos's debt has decreased by 17% YoY and by 2% from the previous quarter
ALLK's EPS has surged by 58% year-on-year but it is down by 40% since the previous quarter
The net income has grown by 42% YoY but it has contracted by 12% from the previous quarter
The company's quick ratio fell by 50% YoY and by 44% QoQ
The equity has declined by 46% year-on-year and by 24% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.allakos.com
Peers: TRAW

Key stats

What are the main financial stats of ALLK
Market
Shares outstanding
87.87M
Market cap
$93.59M
Enterprise value
$65.36M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.55
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$196.05M
EBITDA
-$188.42M
Free cash flow
-$117.07M
Per share
EPS
-$2.14
Free cash flow per share
-$1.35
Book value per share
$1.93
Revenue per share
$0
TBVPS
$2.81
Balance sheet
Total assets
$243.61M
Total liabilities
$74.79M
Debt
$38.22M
Equity
$168.82M
Working capital
$143.31M
Liquidity
Debt to equity
0.23
Current ratio
4.92
Quick ratio
4.67
Net debt/EBITDA
0.15
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-62.1%
Return on equity
-80.3%
Return on invested capital
-83.3%
Return on capital employed
-94.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALLK stock price

How has the Allakos stock price performed over time
Intraday
0.47%
1 week
-4.05%
1 month
-14.8%
1 year
-75%
YTD
-60.99%
QTD
-15.48%

Financial performance

How have Allakos's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$196.06M
Net income
-$185.7M
Gross margin
N/A
Net margin
N/A
The net income has grown by 42% YoY but it has contracted by 12% from the previous quarter
The operating income has grown by 39% YoY but it has contracted by 11% from the previous quarter

Growth

What is Allakos's growth rate over time

Valuation

What is Allakos stock price valuation
P/E
N/A
P/B
0.55
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ALLK's EPS has surged by 58% year-on-year but it is down by 40% since the previous quarter
ALLK's price to book (P/B) is 90% less than its 5-year quarterly average of 5.4 and 58% less than its last 4 quarters average of 1.3
The equity has declined by 46% year-on-year and by 24% since the previous quarter

Efficiency

How efficient is Allakos business performance
ALLK's return on equity is down by 29% since the previous quarter but it is up by 29% year-on-year
The return on assets has grown by 29% year-on-year but it has declined by 25% since the previous quarter
The ROIC has grown by 29% YoY but it has contracted by 27% from the previous quarter

Dividends

What is ALLK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALLK.

Financial health

How did Allakos financials performed over time
The current ratio has shrunk by 52% YoY and by 47% QoQ
The company's quick ratio fell by 50% YoY and by 44% QoQ
Allakos's debt is 77% less than its equity
ALLK's debt to equity has soared by 53% YoY and by 28% from the previous quarter
The equity has declined by 46% year-on-year and by 24% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.